

# Induction of T-cell memory by a dendritic cell vaccine: a computational model

Francesco Pappalardo<sup>1,\*</sup>, Marzio Pennisi<sup>2,†</sup>, Alessia Ricupito<sup>3</sup>, Francesco Topputo<sup>4</sup> and Matteo Bellone<sup>5</sup>

<sup>1</sup>Department of Drug Science and <sup>2</sup>Department of Mathematics and Computer Science, University of Catania, 95125 Catania, <sup>3</sup>San Raffaele Scientific Institute and Università Vita Salute San Raffaele, 20132 Milan, <sup>4</sup>Politecnico di Milano, 20133 Milano and <sup>5</sup>San Raffaele Scientific Institute, 20132 Milan, Italy

Associate Editor: Ziv Bar-Joseph

## 1 INTRODUCTION

In the past years both therapeutic and preventive vaccines have been developed with the aim to fight and prevent different types of cancers (Kahn, 2009; Kantoff, 2010; Kenter *et al.*, 2009). The power of vaccines relies on their ability to stimulate a strong and long-lasting antigen-specific immune response, mediated both by B and T lymphocytes. Although induction of a protective titer of neutralizing antibodies is the main objective of most of the vaccines against infectious agents, including vaccines to carcinogenic human papillomavirus and hepatitis B virus, which also protect from cervical and liver cancer, respectively (Lollini *et al.*, 2011),

evidence in humans that antibodies induced by a vaccine can contribute to antitumor immunity is scanty (Schoenfeld *et al.*, 2010). Conversely, the major goal of both prophylactic and therapeutic vaccines against non-infectious tumors, which account for ~80% of all tumors (Lollini *et al.*, 2011), is to induce a long-lasting antigen-specific CD8 T-cell immunity. In support of this concept, high densities of effector memory CD8<sup>+</sup> cytotoxic T cells are associated with a longer overall survival in several human cancers (Fridman *et al.*, 2012).

Usually, an effective vaccine requires multiple immunizations in the form of prime boost. Several studies have shown that boosting with a different vector carrying the same antigen is better at enhancing immune responses than boosting with the homologous vector. The mechanism underlying this phenomenon is still obscure. Heterologous prime-boost approaches are now widely used in efforts to develop vaccines (Kaufmann, 2010; Sallusto *et al.*, 2010). It is also generally accepted that a strong primary immune response is required to give rise to a large pool of memory cells (Sprent and Surh, 2011). However, what affects the longevity of memory T cells is not fully understood, and much controversy exists regarding the role of antigens in this process (Kaech *et al.*, 2002; Sprent and Surh, 2011; Zinkernagel, 2002). Sustained high amounts of soluble antigens often lead to tolerance or exhaustion both in T and B cells. As a result of exhaustion, antigen-specific T and B cells express a variety of inhibitory receptors such as PD-1, LAG-3, CD244, CD160, TIM-3 and CTLA-4 (Wherry, 2011).

Dendritic cell (DC)-based vaccines have been extensively investigated as potential cancer therapeutic vaccines because of the primary role of DCs as antigen presenting cells (APCs) and their unique ability in T-cell priming (Banchereau and Steinman, 1998). DCs pulsed with the antigen of choice induce a potent antigen-specific immune response and favor the generation of the memory pool. This stems from the asymmetric division of engaged naive T cells into effector and memory cells (Chang *et al.*, 2007). Several phase II clinical trials based on the use of DCs pulsed with tumor-associated antigens are ongoing (Finn, 2008). Moreover, Sipuleucel-T (Provenge, Dendreon, Inc.), an autologous APC-based vaccine has been the first vaccine approved by the Food and Drug Administration for the treatment of cancer patients. In a phase III trial in patients affected by castration-resistant prostate cancer, Sipuleucel-T gave a 4.1 month benefit in overall survival relative to a control arm that

Received on July 26, 2013; revised on December 18, 2013; accepted on January 26, 2014

\*To whom correspondence should be addressed.

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

received unpulsed APCs. However, no significant effects on the time to objective disease progression were observed (Kantoff, 2010). These promising results also suggest that some fundamental biological questions remain unanswered. For DC-based vaccines, it is not yet known whether booster immunizations should consist of DCs or other means. It has been reported that antigen-bearing DCs are rapidly eliminated by antigen-specific cytotoxic T lymphocytes (CTLs) when injected in previously vaccinated mice (Guarda *et al.*, 2007; Yang *et al.*, 2006), therefore, arguing for a reduced effectiveness of DC-based boosts. Jouanneau *et al.* (2006) observed in the GL26 model that DCs are essential for the priming, but they are less effective than tumor cell lysate alone in boosting the antitumor immune response and for the induction of long-term immune memory. Another unsolved issue is the frequency of boosting. It has been reported that repeated immunizations result in increased frequencies of memory T cells (Masopust *et al.*, 2006; Wirth *et al.*, 2010). However, overstimulation can drive memory T cells toward terminal differentiation such as activation-induced cell death, fratricide or exhaustion (Overwijk and Restifo, 2001; Wherry, 2011).

To address these biological issues, we started analyzing the ability of DC-based vaccines to induce a long-lasting antigen-specific immune response in mice. As immunological readout of antigen-primed and functional T cells, we measured the interferon gamma (IFN- $\gamma$ ) contained in sera of vaccinated mice, and the frequency of CD8<sup>+</sup>CD44<sup>+</sup> T cells able to release IFN- $\gamma$  upon *ex vivo*-specific antigen challenge (Camporeale *et al.*, 2003). Preliminary experiments suggested that to optimize the best boosting strategy, we would have had to set many experiments each lasting several months. To investigate these biological problems, as a first step, we began by setting up an *in silico* model capable to describe the biological phenomena observed in the animal model. The aim of the model is to verify the memory T-cell induction hypothesis by a DC-based vaccine observed *in vivo* and to give new suggestions on the designing of boosting strategies. During the past decades, several approaches have been devoted to model the immune system or parts of it, with mathematical equation-based models representing the largest slice among these approaches. Differential equation-based models usually reproduce the dynamics of the average concentrations of the immune-system-involved entities over time, to obtain the main aspects of the immune response. Simple models based on systems of ordinary or partial differential equations can be easily analyzed to obtain, for example, asymptotic behaviors. On the other hand, for more complex scenarios, it is usually difficult to build complex ordinary differential equations (ODE)-based models, as well as incorporate new aspects. The trade-off between an accurate biological representation and the mathematical feasibility may lead to biologically useless models or to mathematically intractable models.

Cellular automata (CA) or agent-based models represent a large class of discrete modeling techniques where each entity is followed individually, and global behaviors are obtained from local behaviors of all involved entities. In this way, it is possible to model the immune system in much more detail, allowing it to determine behavior distribution (and not just the average). Moreover, it is easy to add and remove new entities and non-linear interactions, to expand or update the model to the last biological insights, leaving the problem computationally

tractable. Cellular automata and agent-based models can be successfully used to simulate without any problems the receptor diversity of the immune repertoire, opening the door to natural scale simulations. An example of approaches in this direction is discussed in (Halling-Brown *et al.*, 2010). However, even such approaches have their own flaws. Because of the lack of a solid mathematical theory, they miss tools allowing any asymptotic analysis, and require considerable computational power to simulate individual agents, in particular for large-scale simulations. Some good review articles that can introduce the reader to the modeling techniques of the immune system are presented in Germain *et al.* (2011), Lundegaard *et al.* (2007), and Perelson and Weisbuch (1997).

The problem we are dealing with requires the ability to uniquely represent the immune response of CTLs specific for the immunodominant Tag-IV antigen from the oncovirus SV40 [Mylin *et al.* (1995), and also *in vivo* measurements refer to this]. This is a valid argument for supporting the assumption that a monoclonal model based on ODE described in this article can be considered adequate. The ODE model includes all the relevant entities (such as activated CTLs and memory T cells) needed to confirm the presence of immunological memory. We simulated the biological behavior in the presence and in the absence of memory T cells.

## 2 METHODS

### 2.1 Model description

To model antigen-specific CTL activation and differentiation into memory T cells on vaccination with pulsed DCs, we developed a model based on a system of six ODEs for six different populations: pulsed DCs ( $D_i$ ) in the injection point, pulsed DCs ( $D_p$ ) in the presenting locations, naive CTLs ( $T_n$ ), activated CTLs ( $T_a$ ), memory T cells ( $T_m$ ) and IFN- $\gamma$  ( $I$ ).

Equations (1) and (2) deal with the pulsed DCs at the injection point and the presenting location, respectively. These two equations are used to model the injection of pulsed DCs into the host and their consecutive migration from the injection point to the site where presentation to CTLs occurs (i.e. lymph nodes).  $D_i$  [Equation (1)] are injected according to the function  $k_{in}(t, q)$  that introduces into the system  $q$  pulsed DCs, if, according to the administration protocol, at time  $t$  an injection is scheduled.  $D_i$  then migrate to presenting locations (term  $-\alpha_{50}D_i$ ). They can also disappear from natural death (term  $-\alpha_1D_i$ ).

$$\frac{dD_i}{dt} = k_{in}(t, q) - \alpha_{50}D_i - \alpha_1D_i \quad (1)$$

Equation (2) models the behavior of pulsed DCs into the presenting location.  $D_p$  are estimated on the basis of migrating  $D_i$  (term  $\alpha_{50}D_i$ ) and disappear from the system for multiple causes, such as natural death (term  $-\alpha_1D_p$ ).

$$\frac{dD_p}{dt} = \alpha_{50}D_i - \alpha_1D_p \quad (2)$$

We initially considered the possibility to model the migration process using delay differential equations, by adding in Equation (2) (term  $\alpha_{50}D_i$ ) a time delay of  $\sim 2-4$  h. However, we abandoned this approach because after some numerical simulations, we noted only negligible differences between results obtained with and without time delay. This is probably because such a short time delay becomes insignificant in respect to the time-scale of the experiment (1 year).

Equation (3) models the antigen-specific naive CTLs behavior ( $T_n$ ). In general when naive CTLs are activated, they are replaced by means of hematopoiesis to keep the naive CTLs number almost constant as specified in the leukocyte formula. Of course, this does not mean that the newborn CTLs will share the same MHC/antigen complex specificity of previously activated cells. Present immunological knowledge cannot predict whether and when a CTL will be replaced by one of the same specificity. Moreover, cell receptors are randomly selected by DNA recombinations. Hence, it is feasible to suppose that after a reasonable time window, the level of antigen-specific CTLs will approach to the same initial level. Finally, this is in line with the fact that the immunological repertoire is almost specific for each individual.

The term  $h_1(T_{n0} - T_n)$  represents the recovery rate. Under safe conditions (absence of the pathogen), the number of T cells tends to a given value  $T_{n0}$ . When antigenic presentation by  $D_p$  occurs, naive T cells are activated (term  $-\alpha_5 D_p T_n$ ). We note here that Equation (3) takes into account only a small portion of naive T-cell population composed by those cells whose receptor is able to recognize the specific antigen and not the entire T-cell population.

$$\frac{dT_n}{dt} = h_1(T_{n0} - T_n) - \alpha_5 D_p T_n \quad (3)$$

Activated CTLs ( $T_a$ ) are modeled by Equation (4). They appear in the system as a consequence of the antigenic presentation to  $T_n$  by  $D_p$  cells (term  $-\alpha_5 D_p T_n$ ) and can disappear from the system due to death ( $-a_3 T_a$ ). As a consequence of activation, a small portion of activated T cells can become memory cells ( $-a_{20} T_a$ ).

$$\frac{dT_a}{dt} = \alpha_5 D_p T_n - a_{20} T_a - a_3 T_a \quad (4)$$

Memory CTLs [Equation (5)] are estimated on the basis of activated T cells (term  $a_{20} T_a$ ) and then disappear from the model because of multiple causes, among which is natural death ( $-a_{21} T_m$ ).

$$\frac{dT_m}{dt} = a_{20} T_a - a_{21} T_m \quad (5)$$

The last equation [Equation (6)] describes IFN- $\gamma$  dynamics. The quantity of IFN- $\gamma$  released by CTLs is taken as an outcome of the *ex vivo* experiment, and it is used to estimate the number of activated T cells. To compare our results with *ex vivo* observation, we modeled IFN- $\gamma$  dynamics as follows. IFN- $\gamma$  is released by activated and memory T cells that are supposed to release the same quantity of IFN- $\gamma$  [term  $h_{10}(T_a + T_m)$ ] and disappear from the model for natural degradation (term  $-\alpha_{10} I$ ).

$$\frac{dI}{dt} = h_{10}(T_a + T_m) - \alpha_{10} I \quad (6)$$

It is worth mentioning here that the capacity to endow the host with the ability to learn through multiple encounters, and then generate memory, is in general not representable by ODEs. This important aspect has been analyzed using, for example, agent-based modeling (Palladini *et al.*, 2010; Pennisi *et al.*, 2010). We modeled the learning phase that arises from the multiple encounters of T cells with targets cells by coding that into coefficients that were tuned to reproduce the fraction of memory T cells generated and observed in the mouse; the memory is then represented as the activation of dormant pathways.

Parameter values are shown in Table I and have been set at reasonable values based on results coming from the literature, from the observation of the *in vivo* experiments and from our past experience (Castiglione *et al.*, 2012; Halling-Brown *et al.*, 2010; Pappalardo *et al.*, 2006, 2009a, b, 2010, 2011, 2012; Pennisi *et al.*, 2008, 2009).

Numerical simulations start at week 8 ( $t_0 = 0$ ), time of the first injection of pulsed DCs. The time-length of the simulations has been set to 360 days. The physical time step for the simulations is  $\Delta(t) = 1$  day. To solve numerically the ODE system, we used Berkeley Madonna software.

**Table 1.** ODE model parameters

Parameter	Value
$Q$	500
$a_1$	$\ln(2)/7$
$a_{50}$	0.15
$h_1$	0.015
$a_5$	0.005
$a_3$	$\ln(2)/1.7$
$a_{20}$	0.03
$a_{21}$	$\ln(2)/10$
$h_{10}$	30
$a_{10}$	$\ln(2)/0.375$

*Note:*  $q$  represents the number of injected pulsed DCs/ml; it was tuned with *in vivo* results.  $a_1$  is the pulsed DCs death rate (half-life  $\sim 7$  days) (Merad and Manz, 2009).  $a_{50}$  is the migration rate of Di toward presentation location; it was tuned.  $h_1$  is the T-naive cells recover rate; it was tuned.  $a_5$  is the CTL activation rate; it was tuned.  $a_3$  is the activated T-cell death rate (half-life  $\sim 2$  days) (DeBoer *et al.*, 2003).  $a_{20}$  is the memory T-cell differentiation rate; it was tuned.  $a_{21}$  is the memory T-cell death rate (half-life 8 weeks); it was tuned.  $h_{10}$  is the IFN- $\gamma$  quantity released by T cells (fg/ml) (Pennisi *et al.*, 2010).  $a_{10}$  is the IFN- $\gamma$  degradation rate (half-life  $\sim 9$  h).

Initial conditions have been set to 0 for all populations except for  $T_m$ , where  $T_m(0) = T_{m0}$ . Because Tag-IV is an antigen specifically designed to give rise to a strong immune response, we supposed that  $\sim 20\%$  of the total population of naive CTLs was potentially able to recognize the antigen. Supposing a total population of  $\sim 400$  naive CD8 T cells per  $mm^3$ , we set up  $T_{m0} = 80$ . The differentiation rate of activated CTLs ( $a_{20}$ ) has been tuned up in such a way that the total number of newborn memory T cells for each injection of pulsed DCs is  $\sim 5\%$  of the maximum number of activated T cells for each injection. Moreover, to simulate lack of memory,  $a_{20}$  has been set to 0. The parameters that we defined as ‘tuned’ are free parameters, i.e. they were set to fit the experimental data. We highlight here that for these parameters there are no measures in the literature.

It is worth noting that we used the levels and the proportions of IFN- $\gamma^+$  cells and  $K^b/Tag^+$  cells at week 9 to calibrate the model and the same levels and proportions at week 18 to validate the model results.

## 2.2 LHS-PRCC sensitivity analysis

To understand which parameter may be considered fundamental in this process, it is important to analyze the sensitivity of the model to variation of parameters. Classical sensitivity analysis is usually done by varying a given parameter in reasonable ranges and keeping the others constant. Obviously, results coming from this kind of analysis are strongly bound to the values of the fixed parameters and different sets of values for the fixed parameters may lead to completely different results.

Partial rank correlated coefficients (PRCC) (Saltelli, 2004) is a statistical sensitivity analysis technique that tries to overcome the limits of classical sensitivity analysis by computing a partial correlation on rank-transformed data between two sets of variables, represented in our case by the model input parameters and the model entities values. The strength of such a methodology is given by the fact that correlation does not depend by a given set of parameters, and therefore, it is possible to estimate how variations in a given parameter may influence the results of the model, despite the value of the other parameters. Nevertheless, the methodology can be, in principle, easily applied and used with any kind of continuous or discrete model.

The methodology we used to perform sensitivity analysis (LHS-PRCC) is briefly described as follows. More information about this

methodology can be found in Marino *et al.* (2008). Parameters space is initially sampled using a Monte-Carlo technique. In this case, we use a technique named Latin-Hypercube-Sampling (LHS) (Mckay *et al.*, 1979). The technique divides the random parameter distributions into  $N$  (where  $N$  represents the chosen sample size) equal probability intervals that are then sampled. The choice for  $N$  should be at least  $k + 1$ , where  $k$  is the number of parameters varied, but usually much larger to ensure accuracy. In our trials, we set  $N = 1000$ .

After sampling, a LHS matrix  $X$  of sampled parameters is built. Each row represents a unique set of variables for the model sampled without replacement.

The model is then solved for each row of  $X$ , and the model output values are stored into an output matrix  $Y$ . Each matrix is then rank-transformed ( $X_R$  and  $Y_R$ ).  $X$  and  $Y$  can be used to calculate the Pearson correlation coefficient.  $X_R$  and  $Y_R$  can be used to calculate the Spearman or rank correlation coefficient and the PRCC.

PRCC between an input parameter  $x_j \in X_R, j \leq k$  and output  $y \in Y_R$  is then computed by considering the residuals  $x_j - \hat{x}_j$  and  $y - \hat{y}$ , where  $\hat{x}_j$  and  $\hat{y}$  are given by the following regression models:

$$\hat{x}_j = c_0 + \sum_{p=1, p \neq j}^k c_p x_p \text{ and } \hat{y} = b_0 + \sum_{p=1, p \neq j}^k b_p x_p$$

Using this methodology, we analyzed the effects of the most important input parameters that most influence the behavior of the released IFN- $\gamma$ . We plotted for these entities the PRCCs over the entire time course of the experiment to see how the sensitivity of parameters changes as system dynamics progresses, and we showed the relative PRCC scatterplots at critical time-points. Results are available in Supplementary Data S1.

### 2.3 Mice and reagents

C57BL/6 mice were purchased from Charles River Italia (Calco, Italy). Animals were treated in accordance with the European Community guidelines and with the approval of the institutional ethical committee. Unless specified, all chemical reagents were from Sigma-Aldrich, and monoclonal antibodies were from BD Pharmingen.

### 2.4 DC preparation

DCs were prepared and characterized as previously described (Camporeale *et al.*, 2003). Briefly, bone marrow cells were seeded into six-well plates in ISCOVE supplemented with penicillin/streptomycin and 10% fetal calf serum (Euroclone, Wetherby, UK), and the growth factors GM-CSF (25 ng/ml) and IL-4 (5 ng/ml; R&D Systems, Minneapolis, MN, USA). Eight hours before retrieval of cells, the pro-maturation factor lipopolysaccharide (1  $\mu$ g/ml) was added to the culture medium. On day 7 of the *in vitro* culture, non-adherent and loosely adherent cells were collected. Culture supernatants were evaluated for mycoplasma contamination by PCR, and positive cultures were discarded.

### 2.5 Immunization protocol

DCs were resuspended in phosphate buffered saline at  $2 \times 10^6$ /ml and pulsed with 2  $\mu$ M of the immunodominant CTL epitope Tag-IV peptide (VVYDFLKC; Research Genetics, Huntsville, AL, USA) for 1 h at 37 C, washed, resuspended in phosphate buffered saline and subsequently injected intradermally (i.d.) into the right flank of mice ( $5 \times 10^5$  DC/mouse).

### 2.6 Schedule of immunization

Eight-week-old C57BL/6 mice were primed by i.d. injection of Tag-IV-pulsed DCs (DC-Tag). Four weeks later the primed mice were boosted with DC-Tag, and this process was repeated every 6 weeks for additional

two times. Animals were killed 7 days after the first vaccination or 6 weeks after each boost.

### 2.7 Flow cytometry analyses

Spleens were collected and processed to single cell suspension. Splenocytes were stained *ex vivo* with phycoerythrin-labeled K<sup>b</sup>/Tag-IV pentamers (ProImmune, Sarasota, FL, USA) in combination with the indicated fluorochrome-labeled monoclonal antibodies, the Dump mixture of antibodies (i.e. CD4, CD19, CD11c and CD11b), the vitality marker To-PRO3 and assessed by flow cytometry. Alternatively, cells were cultured in the absence or in the presence of 2  $\mu$ M Tag-IV peptide for 24 h, of which the last 3 h were in the presence of brefeldin A (5  $\mu$ g/ml). Cells were then surface stained with fluorochrome-conjugated anti-CD4, anti-CD8, anti-CD44, anti-CD62L monoclonal antibodies, fixed and analyzed for IFN- $\gamma$  intracellular cytokine staining. PMA/ionomycin was used as positive control. Dead cells were excluded by physical parameters. IFN- $\gamma$ <sup>+</sup> cells were gated on CD8<sup>+</sup> CD44<sup>+</sup>, viable cells. Cytokine production in the absence of stimulation was considered as background release and subtracted from values obtained by the specific peptides. In all experiments, cells were acquired on a BD FACS Canto<sup>®</sup>.

### 2.8 Statistical analysis of *in vivo* experimental studies

Prism 5.0a software was implemented to conduct statistical analysis on data collected in *ex vivo* immunological assays. Comparison of data collected from the different experimental groups of mice (at least five mice/group) was conducted using the ANOVA, and NewmanKeuls test or the two-tailed Students *t*-test. Values were considered statically significant for  $P < 0.05$ .

### 2.9 Measurements for *in silico* setup

To set up the *in silico* approach, we measured the induction and maintenance of an antigen-specific CTL response in C57BL/6 mice injected with DCs pulsed with Tag-IV, the immunodominant CTL epitope from the SV40 Tag antigen (DC-Tag) (Mylin *et al.*, 1995).

### 2.10 Ethics statement


Wild-type C57BL/6 mice (Charles River Breeding Laboratories, Calco, Italy) were housed in a pathogen-free animal facility and treated in accordance with the European Community guidelines. The *in vivo* experiments were approved by the ethical committee of the Istituto Scientifico San Raffaele (IACUC # 410).

## 3 RESULTS AND DISCUSSION

### 3.1 The biological experiment

Eight-week-old mice were primed with a single i.d. injection of DC-Tag, and a first group was sacrificed 1 week later (Fig. 1A). A substantial amount of CD8<sup>+</sup>CD44<sup>+</sup> T cells were found in the spleen of vaccinated mice that bound K<sup>b</sup>/Tag pentamers (Fig. 1B), therefore, demonstrating to be antigen-experienced and specific for Tag. Among the Tag-specific T cells, ~80% displayed an effector phenotype (i.e. CD62L<sup>-</sup>), whereas >20% were central memory (Fig. 1C). We investigated whether the IFN- $\gamma$  measured in the sera of vaccinated mice could be used as an indicator of the effector function of antigen-specific CD8<sup>+</sup> T cells. The amount of IFN- $\gamma$  in the sera of vaccinated mice 1 week after priming was >3-fold the amount found in naive littermates ( $56.3 \pm 10.8$  versus  $17.2 \pm 2.5$  pg/ml, respectively).





**Fig. 1.** Dynamics of antigen-specific CD8<sup>+</sup> T cells during the vaccination schedule. (A) Schematic representation of the experiment. Eight-week-old C57BL/6 mice were primed by i.d. injection of DC-Tag. Four weeks later, the mice were boosted with DC-Tag and this procedure was repeated twice every six weeks. Groups of animals were killed 1 week after the first injection of DC-Tag (week 9,  $n=5$ ), 1 week after the first boost (week 13;  $n=5$ ), or 6 weeks after each boost (week 18,  $n=13$ ; week 24,  $n=10$  and week 30,  $n=9$ ). (B) Splenocytes from vaccinated mice were investigated for their specificity by staining with  $K^b/Tag^+$  pentamers. Data are reported as percentage  $\pm$  SD of  $K^b/Tag^+$  cells within the gate of CD8<sup>+</sup> T cells. (C) Percentage of effector and central memory CD8<sup>+</sup> T cells within the  $K^b/Tag^+$  cells. The effector function of Tag-specific CD8<sup>+</sup> T cells was assessed *ex vivo* by flow cytometry analysis of intracellular IFN- $\gamma$  production in the presence of Tag-IV. Percentage (D) and total number (F) of IFN- $\gamma$ -producing cells are depicted after electronic gating on CD8<sup>+</sup> CD44<sup>+</sup> viable cells. (E) Percentage of effector and central memory CD8<sup>+</sup> T cells within the IFN- $\gamma$ <sup>+</sup> cells. Data are representative of at least three independent experiments. Statistical analyses were done using the ANOVA, Newman-Keuls test and Student's *t*-test. \*\*\* $P < 0.001$  and \*\* $0.001 < P < 0.01$

However, this value remained stable thereafter and did not mimic the drop in Tag-specific T cells found by pentamer staining at week 18 (Fig. 1B and data not shown). This was likely due to the fact that several cells of the innate and adaptive arms of


the immune system concur in producing IFN- $\gamma$  on vaccination. Thus, we used an *ex vivo* intracellular production assay to investigate the effector function of antigen-specific T cells activated by vaccination. Interestingly, a fraction of CD8<sup>+</sup>CD44<sup>+</sup> T cells similar to that found with  $K^b$  pentamer staining (Fig. 1B) also produced IFN- $\gamma$  on antigen-specific challenge (Fig. 1D) and specifically killed targets expressing the relevant antigen (data not shown), therefore, confirming our previously published data (Rigamonti *et al.*, 2011). To investigate the effects of boosts on the dimension of the antigen-specific memory pool, mice were boosted with DC-Tag 4 weeks later. This time schedule was chosen based on the notion that an ideal memory CTL response requires 4–6 weeks to settle in (Sallusto *et al.*, 2010). In spite of the recent vaccination, 1 week after the first boost the percentage (Fig. 1D) and number (Fig. 1F) of CD8<sup>+</sup>CD44<sup>+</sup> T cells producing IFN- $\gamma$  substantially decreased. Mice were boosted 6 weeks later, and the last group of mice was sacrificed 6 weeks after the third boost (Fig. 1A). As expected from a memory response measured more than a month after immunization (Wirth *et al.*, 2010), the number of Tag-specific splenocytes dropped of almost one log (Fig. 1B), whereas central memory T cells increased (Fig. 1C). A similar proportion between effector and memory T cells was found within the population of IFN- $\gamma$ <sup>+</sup> cells (Fig. 1E), therefore, suggesting that  $K^b/Tag$  and IFN- $\gamma$  stained the same cells. Interestingly, both the percentage (Fig. 1D) and the absolute number (Fig. 1F) of antigen-specific CTL remained stable thereafter, therefore, suggesting that the vaccination procedure allowed the induction of a long-lasting antigen-specific memory response.

### 3.2 The *in silico* experiment


To model CTL activation and differentiation into memory T cells on vaccination with pulsed DCs, we developed a model based on a system of six ODEs for six different populations (for details see Section 2).

**3.2.1 Supporting long last T-memory hypothesis** In Figure 2 we show the ODE immune system behavior for the following entities: DC-Tag in the injection point and where the antigen is presented ( $D_i$  and  $D_p$ , respectively), naive, activated and memory antigen-specific CTLs ( $T_n$ ,  $T_a$  and  $T_m$ ), and the levels of IFN- $\gamma$  released by antigen-specific CTLs (I), starting from week 8 for a period of 1 year. To compare *ex vivo* results with the *in silico* experiments, we evaluated the total number of activated and memory CD8<sup>+</sup> T cells and their percentage measured at week 9 and 18 (Figs. 3 and 4). Figure 3 shows the total number of Tag<sup>+</sup> cells (both activated and memory antigen-specific CTLs) at weeks 9 and 18. Comparing these results with Figure 1B, one can notice that the model qualitatively reproduces the same proportions observed *ex vivo*. Moreover, looking at Figure 4 the percentage of specific memory CTLs follows the same dynamics observed *ex vivo* in Figure 1C. These results are in good agreement with the *ex vivo* data and all together support the immunological memory hypothesis.

**3.2.2 Prediction of the role of the second injection (Boosting) over the pool of memory T cells.** To both investigate the role of the second injection (boosting) over the pool of memory Tag-specific CTLs and to verify the prediction capabilities of the




**Fig. 2.** ODE model dynamics. Dynamics for pulsed DCs, CD8 T cells and IFN- $\gamma$ . (A)  $D_i$  represents the dynamics of injected DCs pulsed with the antigen, whereas  $D_p$  represents their dynamics in the presentation locations, i.e. lymphnodes. (B)  $T_n$  represents the dynamics of naive CTLs,  $T_a$  depicts the dynamics of activated CTLs, whereas  $T_m$  are the memory T cells. (C) Dynamics of IFN- $\gamma$  released by antigen-specific CTLs (I)



**Fig. 3.** Tag-specific activated and memory CD8<sup>+</sup> T cells. Tag-specific activated and memory CD8<sup>+</sup> T cells/mcl ( $T_a + T_m$ ) measured *in silico* at week 9 and 18

mathematical model, we simulated two scenarios. In these simulations we executed, as in previous experiments, the first priming with Dc-Tag at week 8. This priming was followed (or not) by a second injection of Dc-Tag at week 12 (boost). The outcome of the experiment was represented by the number of specific CTLs ( $T_a + T_m$ ) at week 9, and at week 18 both in the presence and absence of the boosting. The simulations showed a lower level of specific memory CTLs in the absence of the boosting (Fig. 5).

A similar experiment was then set up *in vivo*, where the mice were primed at week 8 by DC-Tag. The initial set of mice was divided in three groups. The first group was sacrificed at week 9 (priming) to measure primary response. The second and third groups were left untouched (no boost) or boosted at week 12 with DC-Tag and sacrificed after an additional 6 weeks (week 18). As already showed by the mathematical model, the boosting had a substantial impact on the percentage of CD8<sup>+</sup>CD44<sup>+</sup> CTLs producing IFN- $\gamma$  (Fig. 5), and *in vivo* results reported the same behaviors (from a qualitative point of view) already



**Fig. 4.** Percentage of specific effector and memory CD8<sup>+</sup> T cells. Percentage of specific effector and memory CD8<sup>+</sup> T cells ( $T_a + T_m$ ) measured *in silico* at week 9 and 18. Percentages are in a good agreement with the *ex vivo* results (see Fig. 1C)


observed with the mathematical simulations. Hence, the mathematical model demonstrated was able to anticipate the importance of the second injection in promoting the generation of long-lived memory CTLs.

### 3.3 LHS-PRCC sensitivity analysis

Because activated CTLs release IFN- $\gamma$ , we tracked, using PRCC analysis, the effects of the model parameters on the quantity of the released cytokine. It is worth mentioning here that the results of the analysis we performed are strictly dependent on the four-injection vaccination schedule we have modeled. Results of sensitivity analysis are available as Supplementary Data S1. Here, we only outline the major findings.

**3.3.1 Role of CTL differentiation and death rates over IFN- $\gamma$**  Sensitivity analysis reported that memory CTL differentiation rate coefficient  $a_{20}$ , which gives an estimation of the rate of activated CTLs ( $T_a$ ) that differentiate into memory cells ( $T_m$ ), showed a reduced correlation with IFN- $\gamma$ , especially shortly after every DC-Tag, whereas such a correlation increased with the distance from the vaccine injection. This can be explained by the fact that after every injection, the immune response is mainly mediated by activated CTLs, whereas memory CTLs cells give a minor contribution at this time, especially after the first two injections. Far from injections, the immune response of activated CTLs declines and memory CTLs become the principal cells involved in IFN- $\gamma$  release. Similar considerations also hold when we verified the impact of memory CTL death rate on IFN- $\gamma$ .

**3.3.2 Role of naive CTL recovery rate over IFN- $\gamma$**  The naive cell recovery rate ( $h_1$ ), which refers to the speed at which the immune system reconstitutes the naive CTLs pool with newly generated CTLs, showed almost no correlation between the naive cell recovery rate and the IFN- $\gamma$  production, except for a short period of around week 12, just after the second injection of DCs. At that time the number of  $T_n$  was lower than those related to the other administrations. It is worth noting that higher values of  $h_1$  would



**Fig. 5.** Importance of the second injection over the pool of memory CTLs predicted by the mathematical model (*in silico*) and confirmed by the *in vivo* experiment (animal model). Eight-week-old C57BL/6 mice were primed by i.d. injection of DC-Tag and either killed 1 week later (week 9,  $n=5$ ) or boosted (Boost,  $n=13$ ) or not (No Boost,  $n=13$ ) 4 weeks later, and sacrificed 10 weeks after priming (week 18). For the *in silico* experiment the number of specific memory CTLs ( $T_m + T_a$ ) at week 9, and at week 18 both in presence and absence of the boosting were taken into account. For the *in vivo* experiments, the effector function of Tag-specific CD8<sup>+</sup>T cells was assessed *ex vivo* by flow cytometry analysis of intracellular IFN- $\gamma$  production in the presence of Tag-IV. Percentage of IFN- $\gamma$ -producing cells are depicted after electronic gating on CD8<sup>+</sup>CD44<sup>+</sup> viable cells. (Data are representative of at least three independent experiments. Statistical analyses were done using the Student's *t*-test. \*\*: 0.001 <  $P$  < 0.01)

entitle faster recruitment of specific naive CTLs and would allow higher levels of IFN- $\gamma$ . However, such a parameter cannot be modified *in vivo*. The presence of a positive PRCC correlation when the number of  $T_n$  is low may suggest that the second injection of vaccine is given too early, and it should be advisable to delay the second injection to give more time to the immune system to repopulate the specific naive CTLs population until no correlation is reached. Lack of correlation for the entire period may represent an important achievement in designing a treatment that is effective not only for an individual but **also** for an entire population **because** small variations in the rate of recovery of naive cells for different individuals would not influence the efficacy of the treatment.

#### 4 CONCLUSION

Our *in silico* model showed the ability to predict the dimension of the immune response induced in mice by DC vaccination, and allowed us to define the relative contribution of several parameters (i.e. memory cell differentiation and death rates and naive cell recovery rate) to the success of the prime-boost strategy. It also predicted the role of the second injection (Boost) over the pool of memory T cells. Nevertheless, it allowed the identification of a time window in which boosts may be detrimental (Supplementary Data S1). These findings appear to be consistent

with data reported by us (Kaeche *et al.*, 2002) and (Ricupito *et al.*, 2013a). We have demonstrated that boosting healthy mice every 2 weeks instead of every month hindered persistence of IFN- $\gamma$ -competent memory CD8<sup>+</sup> T cells (Ricupito *et al.*, 2013a). In addition, when vaccinated mice were challenged with melanoma cells, 80% of the mice that had received a monthly boosting rejected the tumor. Conversely, mice treated with tighter vaccination schedules survived similarly to non-boosted mice and remarkably less than mice boosted every month (Ricupito *et al.*, 2013b). One of the advantages of the system is that several entities and variables can be added each time. As an example, it might be interesting to investigate the role of endogenous DCs and the antigen formulation (e.g. synthetic peptide, protein or cell fragment) in T-cell priming induced by the vaccine. It has been reported that the requirement of antigen transfer to endogenous APCs for *in vivo* CTL priming by DC-based vaccines may depend on the antigen formulation (Yewdall *et al.*, 2010). Furthermore, by adding the characteristic of the patient (e.g. age, sex, weight, general health status, stage of cancer, comorbidities and medications) a personalized vaccination schedule might be generated. One limitation of the reported data is that they were obtained modeling a healthy subject, and therefore, they are applicable only for the design of preventive vaccines. The system needs to be challenged against more stringent biological contexts, such as in the presence of minimal residual disease or bulky tumors. Our recent findings suggest that tumor antigens released from the tumor as a consequence of either the tumor-cell turnover or the immune attack already boost memory T cells induced by vaccine priming, and vaccine boosts may be detrimental. On the other hand, the model does not take into account the regulation of T-cell longevity and the peculiarities of the antigens. These issues appear important and future version of the model could incorporate them, as wet experiments reveal their roles.

An additional limit of the study is that it is entirely based on mouse data. There are no published clinical trials in which different vaccination schedules have been compared with induction of long-lasting antitumor immunity. Most of the vaccination protocols tested so far in cancer patients stemmed from the experience with prophylactic vaccines against infectious diseases, which are dissimilar to non-infectious tumors. Thus, reliable preclinical models are needed to investigate the therapeutic efficacy of cancer vaccines. Mice are the experimental tool of choice for the majority of tumor immunologists because of the remarkable similarities between mouse and human immune system. Nevertheless, significant differences exist between mice and humans in immune system development, cell subpopulations of both the innate and adaptive arms and perception of endogenous and exogenous activation signals (Mestas and Hughes, 2004). This should sound a word of caution to avoid over interpreting results obtained in mouse models.

Due to the fact that information is also available for humans on the six different populations we used to develop the related ODEs, our model might be easily tested in the human context and provide useful information for DC-based cancer vaccines.

#### ACKNOWLEDGEMENTS

The authors thank Dr A. Napolitano (San Raffaele Scientific Institute, Milan, Italy) for technical suggestions. A.R. conducted

this study as partial fulfillment of her Ph.D in Molecular Medicine, Program in Basic and Applied Immunology, San Raffaele University, Milan, Italy.

**Funding:** ‘Metodi e Modelli Matematici della Teoria Cinetica per Sistemi Complessi’ (PRIN 2009 to F.P. and M.P.) (in part); Italian Association for Cancer Research, AIRC, Milan (to M.B.); the Ministry of Health, Rome (to M.B.); and the Ministry of University and Research, FIRB, Rome (to M.B.).

**Conflict of Interest:** none declared.

## REFERENCES

- Banchereau, J. and Steinman, R. (1998) Dendritic cells and the control of immunity. *Nature*, **392**, 245–252.
- Camporeale, A. *et al.* (2003) Critical impact of the kinetics of dendritic cells activation on the *in vivo* induction of tumor-specific T lymphocytes. *Cancer Res.*, **63**, 3688–3694.
- Castiglione, F. *et al.* (2012) A modeling framework for immune-related diseases. *Math. Model. Nat. Phenom.*, **7**, 40–48.
- Chang, J. *et al.* (2007) Asymmetric T lymphocyte division in the initiation of adaptive immune responses. *Science*, **315**, 1687–1691.
- DeBoer, R. *et al.* (2003) Different dynamics of CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses during and after acute lymphocytic choriomeningitis virus infection. *J. Immunol.*, **171**, 3929–3935.
- Finn, O. (2008) Cancer immunology. *N. Engl. J. Med.*, **358**, 2704–2715.
- Fridman, W. *et al.* (2012) The immune contexture in human tumours: impact on clinical outcome. *Nat. Rev. Cancer*, **12**, 298–306.
- Germain, R.N. *et al.* (2011) Systems biology in immunology: a computational modeling perspective. *Annu. Rev. Immunol.*, **29**, 527–585.
- Guarda, G. *et al.* (2007) L-selectin-negative CCR7<sup>-</sup> effector and memory CD8<sup>+</sup> T cells enter reactive lymph nodes and kill dendritic cells. *Nat. Immunol.*, **8**, 743–752.
- Halling-Brown, M. *et al.* (2010) Immunogrid: towards agent-based simulations of the human immune system at a natural scale. *Philos. Trans. A Math. Phys. Eng. Sci.*, **368**, 2799–2815.
- Jouanneau, E. *et al.* (2006) Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. *Cancer Immunol. Immunother.*, **55**, 254–267.
- Kaech, S. *et al.* (2002) Effector and memory T-cell differentiation: implications for vaccine development. *Nat. Rev. Immunol.*, **2**, 251–262.
- Kahn, J. (2009) HPV vaccination for the prevention of cervical intraepithelial eoplasia. *N. Engl. J. Med.*, **361**, 271–278.
- Kantoff, P. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.*, **363**, 411–422.
- Kaufmann, S. (2010) Future vaccination strategies against tuberculosis: thinking outside the box. *Immunity*, **33**, 567–577.
- Kenter, G. *et al.* (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N. Engl. J. Med.*, **361**, 1838–1847.
- Lollini, P. *et al.* (2011) Vaccines and other immunological approaches for cancer immunoprevention. *Curr. Drug Targets*, **13**, 1957–1973.
- Lundegaard, C. *et al.* (2007) Modeling the adaptive immune system: predictions and simulations. *Bioinformatics*, **23**, 3265–3275.
- Marino, S. *et al.* (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. *J. Theor. Biol.*, **254**, 178–196.
- Masopust, D. *et al.* (2006) Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. *J. Immunol.*, **177**, 831–839.
- Mckay, M. *et al.* (1979) Comparison of 3 methods for selecting values of input variables in the analysis of output from a computer code. *Technometrics*, **21**, 239–245.
- Merad, M. and Manz, M. (2009) Dendritic cell homeostasis. *Blood*, **113**, 3418–3427.
- Mestas, J. and Hughes, C. (2004) Of mice and not men: differences between mouse and human immunology. *J. Immunol.*, **172**, 2731–2738.
- Mylin, L. *et al.* (1995) Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2K<sup>b</sup>-restricted determinant in simian virus 40 tumor antigen. *Virology*, **208**, 159–172.
- Overwijk, W. and Restifo, N. (2001) Creating therapeutic cancer vaccines: notes from the battlefield. *Trends Immunol.*, **22**, 5–7.
- Palladini, A. *et al.* (2010) *In silico* modeling and *in vivo* efficacy of cancer-preventive vaccinations. *Cancer Res.*, **70**, 7755–7763.
- Pappalardo, F. *et al.* (2006) Genetic algorithm against cancer. *Lect. Notes Comput. Sci.*, **3849**, 223–228.
- Pappalardo, F. *et al.* (2009a) Agent based modeling of atherosclerosis: a concrete help in personalized treatments. *Lect. Notes Comput. Sci.*, **5755**, 386–396.
- Pappalardo, F. *et al.* (2009b) ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. *Brief. Bioinform.*, **10**, 330–340.
- Pappalardo, F. *et al.* (2010) Vaccine protocols optimization: *in silico* experiences. *Biotechnol. Adv.*, **28**, 82–93.
- Pappalardo, F. *et al.* (2011) SimB16: modeling induced immune system response against B16-melanoma. *PLoS One*, **6**, e26523.
- Pappalardo, F. *et al.* (2012) Mathematical and computational models in tumor immunology. *Math. Model. Nat. Phenom.*, **7**, 186–203.
- Pennisi, M. *et al.* (2008) Optimal vaccination schedules using simulated annealing. *Bioinformatics*, **24**, 1740–1742.
- Pennisi, M. *et al.* (2009) Searching of optimal vaccination schedules: application of genetic algorithms to approach the problem in cancer immunoprevention. *IEEE Eng. Med. Biol. Mag.*, **28**, 67–72.
- Pennisi, M. *et al.* (2010) Modeling the competition between lung metastases and the immune system using agents. *BMC Bioinformatics*, **11** (Suppl. 7), S13.
- Perelson, A.S. and Weisbuch, G. (1997) Immunology for physicists. *Rev. Mod. Phys.*, **69**, 1219–1267.
- Ricupito, A. *et al.* (2013a) Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. *Cancer Res.*, **73**, 3545–3554.
- Ricupito, A. *et al.* (2013b) Boosting anticancer vaccines: too much of a good thing? *Oncimmunology*, **2**, e25032.
- Rigamonti, N. *et al.* (2011) Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. *Clin. Cancer Res.*, **17**, 1012–1023.
- Sallusto, F. *et al.* (2010) From vaccines to memory and back. *Immunity*, **33**, 451–463.
- Saltelli, A. (2004) *Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models*. Wiley, Hoboken, NJ.
- Schoenfeld, J. *et al.* (2010) Active immunotherapy induces antibody responses that target tumor angiogenesis. *Cancer Res.*, **70**, 10150–60.
- Sprent, J. and Surh, C. (2011) Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. *Nat. Immunol.*, **12**, 478–484.
- Wherry, E. (2011) T cell exhaustion. *Nat. Immunol.*, **12**, 492–496.
- Wirth, T. *et al.* (2010) Modulating numbers and phenotype of CD8<sup>+</sup> T cells in secondary immune responses. *Eur. J. Immunol.*, **40**, 1916–1926.
- Yang, J. *et al.* (2006) Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8<sup>+</sup> T cells *in vivo*. *Proc. Natl Acad. Sci. USA*, **103**, 147–152.
- Yewdall, A. *et al.* (2010) CD8<sup>+</sup> T Cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. *PLoS One*, **5**, e11144.
- Zinkernagel, R. (2002) On differences between immunity and immunological memory. *Curr. Opin. Immunol.*, **14**, 523–536.